Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 275 recruiting now early-phase tilt #4 of 28,963 conditions

Prostate Cancer: early-phase trial registry

275 of 749 indexed Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4 of 28,963 conditions by registered trial count.

749 US clinical trials · 275 currently recruiting · #4 of 28,963 conditions by registered trial count

Prostate Cancer: 749 US clinical trials tracked, 275 recruiting.

Prostate Cancer is the subject of 749 registered US clinical trials on ClinicalTrials.gov, 275 of them currently open to new participants. 75 are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 53 of these trials.

Open enrollment, early-phase tilt

Prostate Cancer has 749 registered US clinical trials, 275 of them open to new participants right now, about 37% of the total.

275
recruiting participants now
37%
of trials open to enrollment
75
in Phase 3-4 (later-stage)
53
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #4 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Prostate Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Prostate Cancer recruits in line with its size-band peers.

    275 of 749 indexed trials (36.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Prostate Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 53 of 749 trials (7.1%). 283 distinct sponsors appear on at least one study for this condition label.

  3. Typical Prostate Cancer enrolment sits around 82 participants.

    Median target enrolment is 82 among the 736 trials that report a genuine target (sentinel values excluded). 389 of those (52.9%) plan for fewer than 100 participants.

  4. Prostate Cancer research is mostly interventional.

    628 interventional and 121 observational studies make up this index (83.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1156Phase 2188Phase 362Phase 413

Open and recent trials

749 total, page 11 of 15

COMPLETED NA 316 participants

PACCT: Partnering Around Cancer Clinical Trials

Susan Eggly

NCT02906241

COMPLETED NA 307 participants

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

Accuray Incorporated

NCT00643617

COMPLETED Phase 3 306 participants

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

M.D. Anderson Cancer Center

NCT00002855

COMPLETED NA 301 participants

OPTimizing Treatment Focused Genetic Testing IN Cancer

Dana-Farber Cancer Institute

NCT04066361

COMPLETED NA 300 participants

Redes III Patient Navigator Qol Study

The University of Texas Health Science Center at San Antonio

NCT02275754

COMPLETED Phase 2 300 participants

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

Phoenix Molecular Imaging

NCT01530269

COMPLETED Phase 3 290 participants

Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT00142506

COMPLETED NA 286 participants

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

GenomeDx Biosciences

NCT02080689

COMPLETED Phase 3 282 participants

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Eastern Cooperative Oncology Group

NCT00060398

COMPLETED 274 participants

Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients

Myriad Genetic Laboratories

NCT02209584

COMPLETED NA 263 participants

Prostate Cancer: Family Care for Patients and Spouses

University of Michigan

NCT00708968

COMPLETED Early Phase 1 250 participants

PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

Mayo Clinic

NCT03768349

COMPLETED Phase 2 246 participants

A Randomized Study of the Efficacy of Low Venous Pressure General Anesthesia Versus Combined Spinal-Epidural Anesthesia in Decreasing Blood Loss During Prostate Surgery

Memorial Sloan Kettering Cancer Center

NCT00200187

COMPLETED Phase 4 243 participants

Local Anesthesia for Prostate Biopsy

Mayo Clinic

NCT00422708

COMPLETED Phase 3 242 participants

Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy

Radiation Therapy Oncology Group

NCT00931528

COMPLETED Phase 3 239 participants

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Radiation Therapy Oncology Group

NCT01546987

COMPLETED NA 228 participants

Proton Therapy for Low and Intermediate Risk Prostate Cancer

University of Florida

NCT00693238

COMPLETED 224 participants

Prostate Cancer Survey

University of Maryland, Baltimore

NCT03128710

COMPLETED NA 224 participants

Technology Based Psychosocial Intervention for Symptom Management and HRQOL in Men Living With Advanced Prostate Cancer

Northwestern University

NCT03149185

COMPLETED NA 222 participants

The Impact of Low Pressure Pneumo in RARP

Metro Health, Michigan

NCT03370016

COMPLETED Phase 3 213 participants

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Alliance for Clinical Trials in Oncology

NCT00377156

COMPLETED Phase 2 180 participants

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

M.D. Anderson Cancer Center

NCT01751438

COMPLETED Phase 3 176 participants

PROvenge Treatment and Early Cancer Treatment

Dendreon

NCT00779402

COMPLETED NA 167 participants

Study of Hypofractionated Proton Beam Radiation Therapy for Prostate Cancer

Loma Linda University

NCT00831623

COMPLETED NA 162 participants

Trial of Community Health Worker-led Decision Coaching

NYU Langone Health

NCT03726320

COMPLETED NA 161 participants

Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men

Xavier University of Louisiana.

NCT03869216

COMPLETED 157 participants

Reduction of Prostate Biopsy Morbidity

Maimonides Medical Center

NCT03913039

COMPLETED Phase 3 154 participants

Diet and PSA Levels in Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

NCT00003367

COMPLETED 150 participants

Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods

National Human Genome Research Institute (NHGRI)

NCT00022919

COMPLETED 150 participants

Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer

Mayo Clinic

NCT03159676

COMPLETED Phase 1 143 participants

Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT01317199

COMPLETED Phase 2 141 participants

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Nymox Corporation

NCT01620515

COMPLETED Phase 2 140 participants

Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer

University of Michigan

NCT01825642

COMPLETED Phase 2 138 participants

External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

Radiation Therapy Oncology Group

NCT00006365

COMPLETED Phase 2 131 participants

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Janssen Biotech

NCT01314118

COMPLETED Phase 4 131 participants

A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy

Astellas Pharma

NCT00106392

COMPLETED Phase 2 128 participants

FACBC PET/CT for Recurrent Prostate Cancer

David M. Schuster, MD

NCT00562315

COMPLETED NA 126 participants

Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.

NYU Langone Health

NCT01964638

COMPLETED 120 participants

Understanding the Value of Community Vital Signs in Primary Care

Virginia Commonwealth University

NCT02512835

COMPLETED Phase 2 119 participants

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Progenics Pharmaceuticals

NCT01695044

COMPLETED Phase 4 118 participants

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Watson Pharmaceuticals

NCT01161563

COMPLETED Early Phase 1 116 participants

18F-DCFBC PET/CT in Prostate Cancer

National Cancer Institute (NCI)

NCT02190279

COMPLETED Phase 2 114 participants

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Dana-Farber Cancer Institute

NCT02499497

COMPLETED NA 109 participants

Study of Carbon Dioxide Exchange Patterns During Robotic Prostatectomies

OhioHealth

NCT02114164

COMPLETED 108 participants

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

Janssen Scientific Affairs

NCT02663193

COMPLETED NA 107 participants

A Pilot Study of Geriatric Specific Interventions for Quality of Life in Elderly Patients With Cancer

Memorial Sloan Kettering Cancer Center

NCT00984321

COMPLETED NA 106 participants

Developing an Imaging-Based Tool to Identify Areas for Prostate Cancer Biopsy

University of Chicago

NCT03585660

COMPLETED Phase 2 104 participants

Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer

Dendreon

NCT00901342

COMPLETED 100 participants

Exploring Men s Prostate Cancer Genetic Risk Perceptions

H. Lee Moffitt Cancer Center and Research Institute

NCT06764992

COMPLETED 98 participants

Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy

Mayo Clinic

NCT01777802

← Previous Page 11 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 156
Phase 2 188
Phase 3 62
Phase 4 13

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Prostate Cancer right now

275 recruiting of 749 indexed (37% open).

Phase mix: 75 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (53 trials), 9 others listed. 50 shown below, recruiting first. #4 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Prostate Cancer?

PlainTrial tracks 749 US clinical trials for Prostate Cancer, of which 275 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Prostate Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.